41
Participants
Start Date
March 28, 2016
Primary Completion Date
October 3, 2018
Study Completion Date
October 3, 2018
PQR309
Dual phosphatidylinositol 3-kinase phosphoinositide 3-kinase/ mammalian target of rapamycin Inhibitor (= PI3K/mTOR Inhibitor)
Eribulin
non.taxane microtubule dynamics inhibitor
Hospital Universitarsi Vall d'Hebron, Barcelona
Insitut Català d´Oncologia, Barcelona
Fundación Instituto Valenciano de Oncología, Valencia
Barts Cancer Institute, London
Churchill hospital, Oxford
Lead Sponsor
Collaborators (1)
Hospital Universitario Ramon y Cajal
OTHER
Hospital Universitari Vall d'Hebron Research Institute
OTHER
Institut Català d'Oncologia
OTHER
Churchill Hospital
OTHER
Barts Cancer Institute
OTHER
Fundación Instituto Valenciano de Oncología
OTHER
PIQUR Therapeutics AG
INDUSTRY